Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365703 | 0.92 | PIK3C3 (0.40) | ATRPIK3C3GCKHDAC3HDAC1 | |
| SCHEMBL19365798 | 0.91 | PIK3C3 (0.38) | ATRPIK3C3HDAC3HDAC1HDAC2 | |
| SCHEMBL19364885 | 0.91 | PIK3C3 (0.35) | ATRPIK3C3HDAC3HDAC1HDAC2 | |
| SCHEMBL19670409 | 0.88 | PRMT5 (0.42) | ATRGRM5KDM4ELCK | |
| SCHEMBL19365778 | 0.87 | HDAC3 (0.39) | PIK3C3HDAC3HDAC1HDAC2 | |
| SCHEMBL19364834 | 0.87 | ALDH1A1 (0.39) | ATRALDH1A1HDAC2 | |
| SCHEMBL19365309 | 0.87 | CNR2 (0.40) | ATRGRM5KDM4EALDH1A1HDAC3 | |
| SCHEMBL19365441 | 0.85 | ATR (0.48) | ATRHDAC3HDAC1HDAC2 | |
| SCHEMBL19706240 | 0.85 | WNT1 (0.40) | ATRGRM5ALDH1A1HDAC3HDAC1 | |
| SCHEMBL19365471 | 0.85 | ATR (0.36) | ATRGRM5LCKALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ATR 1867/4885PIK3C3 4778/4885GRM5 3471/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | ATR 1867/4885PIK3C3 4778/4885GRM5 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.